HARP Study: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==HARP Study== ===Objective=== The Harvard Atherosclerosis Reversibility Project (HARP) aimed at studying the effect of intensi..."
 
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
No edit summary
 
(One intermediate revision by the same user not shown)
Line 3: Line 3:


{{CMG}}
{{CMG}}
==HARP Study==
==Objective==
===Objective===
The Harvard Atherosclerosis Reversibility Project (HARP) aimed at studying the effect of intensive lipid lowering therapy in normocholesterolemic patients and its effect on angiographic progression of [[atherosclerosis]].  
The Harvard Atherosclerosis Reversibility Project (HARP) aimed at studying the effect of intensive lipid lowering therapy in normocholesterolemic patients and its effect on angiographic progression of [[atherosclerosis]].  


===Methods===
==Methods==
HARP was a randomized placebo-controlled trial wherein 91 normocholesterolemic patients, with total serum [[cholesterol]] levels less than 250 mg/dL, were selected and treated with a stepwise regimen of diet, [[pravastatin]], [[nicotinic acid]], [[cholestyramine]] and [[gemfibrozil]] for 2.5 years. Repeat coronary angiograms were performed to assess the progression of coronary atherosclerosis.
HARP was a randomized placebo-controlled trial wherein 91 normocholesterolemic patients, with total serum [[cholesterol]] levels less than 250 mg/dL, were selected and treated with a stepwise regimen of diet, [[pravastatin]], [[nicotinic acid]], [[cholestyramine]] and [[gemfibrozil]] for 2.5 years. Repeat coronary angiograms were performed to assess the progression of coronary atherosclerosis.


===Results===
==Results==
The study found a significant improvement in total cholesterol, [[LDL]]-C and [[HDL]]-C levels, however repeat [[coronary angiogram]]s did not show significant differences in the degree of coronary obstruction, progression of coronary stenosis, regression and clinical cardiac events.  
The study found a significant improvement in total cholesterol, [[LDL]]-C and [[HDL]]-C levels, however repeat [[coronary angiogram]]s did not show significant differences in the degree of coronary obstruction, progression of coronary stenosis, regression and clinical cardiac events.  


===Conclusion===
==Conclusion==
This study concluded that intensive lipid lowering therapy does not alter the rate of progression of coronary stenoses in normocholesterolemic patients.<ref name="pmid7934538">{{cite journal |author=Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH |title=Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group |journal=Lancet |volume=344 |issue=8931 |pages=1182–6 |year=1994 |month=October |pmid=7934538 |doi= |url=}}</ref><ref name="pmid7759696">{{cite journal |author=Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC |title=Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group |journal=J. Am. Coll. Cardiol. |volume=25 |issue=7 |pages=1492–8 |year=1995 |month=June |pmid=7759696 |doi= |url=}}</ref><ref name="pmid7572692">{{cite journal |author=Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH |title=The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group |journal=Am. J. Cardiol. |volume=76 |issue=9 |pages=78C–85C |year=1995 |month=September |pmid=7572692 |doi= |url=}}</ref><ref name="pmid8815751">{{cite journal |author=Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM |title=Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group |journal=Ann. Intern. Med. |volume=125 |issue=7 |pages=529–40 |year=1996 |month=October |pmid=8815751 |doi= |url=}}</ref>
This study concluded that intensive lipid lowering therapy does not alter the rate of progression of coronary stenoses in normocholesterolemic patients.<ref name="pmid7934538">{{cite journal |author=Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH |title=Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group |journal=Lancet |volume=344 |issue=8931 |pages=1182–6 |year=1994 |month=October |pmid=7934538 |doi= |url=}}</ref><ref name="pmid7759696">{{cite journal |author=Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC |title=Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group |journal=J. Am. Coll. Cardiol. |volume=25 |issue=7 |pages=1492–8 |year=1995 |month=June |pmid=7759696 |doi= |url=}}</ref><ref name="pmid7572692">{{cite journal |author=Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH |title=The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group |journal=Am. J. Cardiol. |volume=76 |issue=9 |pages=78C–85C |year=1995 |month=September |pmid=7572692 |doi= |url=}}</ref><ref name="pmid8815751">{{cite journal |author=Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM |title=Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group |journal=Ann. Intern. Med. |volume=125 |issue=7 |pages=529–40 |year=1996 |month=October |pmid=8815751 |doi= |url=}}</ref>


Line 22: Line 21:
[[Category:Lipopedia]]
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:HDL]]
[[Category:Clinical trials]]
[[Category:HDLpedia]]

Latest revision as of 14:36, 21 October 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

HARP Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HARP Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HARP Study

CDC on HARP Study

HARP Study in the news

Blogs on HARP Study

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for HARP Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

The Harvard Atherosclerosis Reversibility Project (HARP) aimed at studying the effect of intensive lipid lowering therapy in normocholesterolemic patients and its effect on angiographic progression of atherosclerosis.

Methods

HARP was a randomized placebo-controlled trial wherein 91 normocholesterolemic patients, with total serum cholesterol levels less than 250 mg/dL, were selected and treated with a stepwise regimen of diet, pravastatin, nicotinic acid, cholestyramine and gemfibrozil for 2.5 years. Repeat coronary angiograms were performed to assess the progression of coronary atherosclerosis.

Results

The study found a significant improvement in total cholesterol, LDL-C and HDL-C levels, however repeat coronary angiograms did not show significant differences in the degree of coronary obstruction, progression of coronary stenosis, regression and clinical cardiac events.

Conclusion

This study concluded that intensive lipid lowering therapy does not alter the rate of progression of coronary stenoses in normocholesterolemic patients.[1][2][3][4]

References

  1. ↑ Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH (1994). "Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group". Lancet. 344 (8931): 1182–6. PMID 7934538. Unknown parameter |month= ignored (help)
  2. ↑ Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC (1995). "Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group". J. Am. Coll. Cardiol. 25 (7): 1492–8. PMID 7759696. Unknown parameter |month= ignored (help)
  3. ↑ Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH (1995). "The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group". Am. J. Cardiol. 76 (9): 78C–85C. PMID 7572692. Unknown parameter |month= ignored (help)
  4. ↑ Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM (1996). "Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group". Ann. Intern. Med. 125 (7): 529–40. PMID 8815751. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=HARP_Study&oldid=909983"